Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224665) IMPROVED PHARMACOKINETICS AND CHOLECYSTOKININ-2 RECEPTOR (CCK2R) TARGETING FOR DIAGNOSIS AND THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/224665 International Application No.: PCT/EP2018/065206
Publication Date: 13.12.2018 International Filing Date: 08.06.2018
IPC:
A61K 38/08 (2006.01) ,C07K 7/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
06
having 5 to 11 amino acids
Applicants:
MEDIZINISCHE UNIVERSITÄT INNSBRUCK [AT/AT]; Innrain 52 6020 Innsbruck, AT
Inventors:
VON GUGGENBERG ZU RIEDHOFEN, Elisabeth; AT
KLINGLER, Maximilian; AT
Agent:
ZEMAN, Steven; DE
Priority Data:
17174973.208.06.2017EP
Title (EN) IMPROVED PHARMACOKINETICS AND CHOLECYSTOKININ-2 RECEPTOR (CCK2R) TARGETING FOR DIAGNOSIS AND THERAPY
(FR) PHARMACOCINÉTIQUE ET CIBLAGE DU RÉCEPTEUR DE LA CHOLÉCYSTOKININE-2 (CCK2R) AMÉLIORÉS POUR LE DIAGNOSTIC ET LA THÉRAPIE
Abstract:
(EN) The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention are incorporated by CCK2R expressing cells, for instance, cancer cells. This allows, for instance, to selectively destroy cancer cells or to selectively image cancer cells that express CCK2R.
(FR) La présente invention concerne des peptidomimétiques de valeur à des fins thérapeutiques et diagnostiques, ainsi que des compositions, des procédés, des utilisations et des kits basés sur ces peptidomimétiques. En particulier, les peptidomimétiques de la présente invention sont incorporés par des cellules exprimant CCK2R, par exemple des cellules cancéreuses. Ceci permet, par exemple, de détruire sélectivement des cellules cancéreuses ou d'imager sélectivement des cellules cancéreuses qui expriment CCK2R.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)